| Literature DB >> 29201747 |
Abstract
AIM: Open access endoscopy allows physicians and general practitioners (GIs) to refer patients for endoscopy without prior outpatient consultation. This system was introduced to reduce waiting time to the procedure and subsequent diagnosis. Concerns have been raised regarding misuse of this system with increasing number of inappropriate referrals and hence more normal examinations, which has implications on a public-funded health system. The aim of this study was to assess the appropriate use of the open access system at a rural New Zealand hospital and to see if the diagnostic yield improves by following the American Society of Gastroenterology (ASGE) guidelines for upper gastrointestinal endoscopy [esophagogastroduodenoscopy (OGD)].Entities:
Keywords: American Society of Gastroenterology; Open access; Upper gastrointestinal endoscopy.
Year: 2016 PMID: 29201747 PMCID: PMC5578583 DOI: 10.5005/jp-journals-10018-1187
Source DB: PubMed Journal: Euroasian J Hepatogastroenterol ISSN: 2231-5047
Table 1: American society of gastroenterology classification of appropriate and not appropriate indications for OGD
| A. Upper abdominal symptoms that persist despite an appropriate trial of therapy. | |
| B. Upper abdominal symptoms associated with other symptoms or signs suggesting structural disease (e.g., anorexia and weight loss) or new-onset symptoms in patients older than 50 years of age. | |
| C. Dysphagia or odynophagia. | |
| D. Esophageal reflux symptoms that persist or recur despite appropriate therapy. | |
| E. Persistent vomiting of unknown cause. | |
| F. Other diseases in which the presence of upper GI pathology might modify other planned management. Examples include patients who have a history of ulcer or GI bleeding who are scheduled for organ transplantation, long-term anticoagulation or nonsteroidal anti-inflammatory drug therapy for arthritis and those with cancer of the head and neck. | |
| G. Familial adenomatous polyposis syndromes. | |
| H. For confirmation and specific histologic diagnosis of radiologically demonstrated lesions: | |
| 1. Suspected neoplastic lesion. | |
| 2. Gastric or esophageal ulcer. | |
| 3. Upper tract stricture or obstruction | |
| I. GI bleeding: | |
| 1. In patients with active or recent bleeding. | |
| 2. For presumed chronic blood loss and for iron deficiency anemia when the clinical situation suggests an upper GI source or when colonoscopy does not provide an explanation. | |
| J. When sampling of tissue or fluid is indicated. | |
| K. Selected patients with suspected portal hypertension to document or treat esophageal varices. | |
| L. To assess acute injury after caustic ingestion. | |
| M. To assess diarrhea in patients suspected of having small-bowel disease (e.g., celiac disease). | |
| N. Treatment of bleeding lesions, such as ulcers, tumors, vascular abnormalities (e.g., electrocoagulation, heater probe, laser photocoagulation, or injection therapy). | |
| O. Removal of foreign bodies. | |
| P. Removal of selected lesions. | |
| Q. Placement of feeding or drainage tubes (e.g., peroral, percutaneous endoscopic gastrostomy, percutaneous endoscopic jejunostomy). | |
| R. Dilation and stenting of stenotic lesions (e.g., with transendoscopic balloon dilators or dilation systems using guide wires). | |
| S. Management of achalasia (e.g., botulinum toxin, balloon dilation). | |
| T. Palliative treatment of stenosing neoplasms (e.g., laser, multipolar electrocoagulation, stent placement). | |
| U. Endoscopic therapy of intestinal metaplasia. | |
| V. Intraoperative evaluation of anatomic reconstructions typical of modern foregut surgery (e.g., evaluation of anastomotic leak and patency, fundoplication formation, pouch configuration during bariatric surgery). | |
| W. Management of operative complications (e.g., dilation of anastomotic strictures, stenting of anastomotic disruption, fistula, or leak in selected circumstances). | |
| EGD is generally not indicated for evaluating: | |
| A. Symptoms that are considered functional in origin (there are exceptions in which an endoscopic examination may be done once to rule out organic disease, especially if symptoms are unresponsive to therapy or symptoms recur that are different in nature from the original symptoms). | |
| B. Metastatic adenocarcinoma of unknown primary site when the results will not alter management. | |
| C. Radiographic findings of: | |
| 1. Asymptomatic or uncomplicated sliding hiatal hernia. | |
| 2. Uncomplicated duodenal ulcer that has responded to therapy. | |
| 3. Deformed duodenal bulb when symptoms are absent or respond adequately to ulcer therapy. | |
| Sequential or periodic EGD may be indicated for: | |
| A. Surveillance for malignancy in patients with premalignant conditions (e.g., Barrett’s esophagus, polyposis syndromes, gastric adenomas, tylosis, or previous caustic ingestion). | |
| Sequential or periodic EGD is generally not indicated for: | |
| A. Surveillance for malignancy in patients with gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia, or previous gastric operations for benign disease. | |
| B. Surveillance of healed benign disease, such as esophagitis and gastric or duodenal ulcer. |
GI: Gastrointestinal; EGD: Esophagogastroduodenoscopy
Table 2: Demographic and clinical characteristics of the study population according to the specialty of the referring physician
| Sex, M/F | 329/236 | 132/322 | |||
| Age, mean ± SD | 61.1 ± 17.3 | 60.3 ± 17.5 | |||
| Main referral indication (%) | |||||
| • Appropriate indication | |||||
| 1. Upper abdominal symptoms persistent despite therapy | 8.8 | 15.4* | |||
| 2. Upper abdominal symptoms associated with symptoms and signs suggesting serious organic disease or in patients aged >45 years | 5.3 | 11* | |||
| 3. Esophageal reflux symptoms persistent or recurrent despite therapy | 1.8 | 4.4 | |||
| 4. Portal hypertension evaluation | 0.9 | 0 | |||
| 5. Active or recent GI bleeding | 23.2 | 0* | |||
| 6. Suspected chronic bleeding | 3.5 | 6.6 | |||
| 7. Dysphagia or odynophagia | 3.5 | 11.9* | |||
| 8. GI assessment in other medical disorders | 1.8 | 2.2 | |||
| 9. Persistent vomiting of unknown cause | 1.8 | 6.6* | |||
| 10. Sclerotherapy or variceal bleeding | 5 | 0 | |||
| 11. Histologic assessment of a neoplasia detected radiologically | 1.8 | 0* | |||
| 12. Others | 1.8 | 3.5 | |||
| • Not appropriate indications | |||||
| 1. Symptoms considered functional | 10.8 | 24.7* | |||
| 2. Surveillance of healed benign lesions | 30.6 | 11.2* | |||
| 3. Others | 3.5 | 2.4 |
*p < 0.01; GI: Gastrointestinal
Table 3: Referral indication for OGD and diagnostic yield according to ASGE guideline criteria
| • Appropriate indication | |||||||||
| 1. Upper abdominal symptoms persistent despite therapy | 11.8 | 66.7 | 1.91 | 0.92 | |||||
| 2. Upper abdominal symptoms associated with symptoms and signs suggesting serious organic disease or in patients aged >45 years | 7.9 | 91.3 | 9.96 | 0.87 | |||||
| 3. Esophageal reflux symptoms persistent or recurrent despite therapy | 2.9 | 76.7 | 3.14 | 0.96 | |||||
| 4. Portal hypertension evaluation | 0.5 | 100 | 10.51 | 0.99 | |||||
| 5. Active or recent GI bleeding | 12.9 | 53.4 | 1.09 | 0.98 | |||||
| 6. Suspected chronic bleeding | 4.9 | 56 | 1.21 | 0.99 | |||||
| 7. Dysphagia or odynophagia | 7.3 | 52.7 | 1.06 | 0.99 | |||||
| 8. GI assessment in other medical disorders | 2.0 | 55 | 1.16 | 0.99 | |||||
| 9. Persistent vomiting of unknown cause | 3.9 | 80 | 3.82 | 0.95 | |||||
| 10. Sclerotherapy or variceal bleeding | 0.5 | 100 | 10.51 | 0.99 | |||||
| 11. Histologic assessment of a neoplasia detected radiologically | 1.0 | 60 | 1.43 | 0.99 | |||||
| 12. Others | 2.6 | 46.2 | 0.81 | 1 | |||||
| 13. Total | 58 | 65 | 1.77 | 0.45 | |||||
| • Not appropriate indications | |||||||||
| 1. Symptoms considered functional | 17 | 38.7 | 0.64 | 1.32 | |||||
| 2. Surveillance of healed benign lesions | 22 | 25.9 | 0.33 | 1.33 | |||||
| 3. Others | 3.0 | 38.7 | 0.64 | 1.01 | |||||
| 4. Total | 42 | 32 | 0.45 | 1.77 |
GI: Gastrointestinal
Table 4: Main endoscopic findings according to appropriateness of the indication
| Clinically relevant | |||||||
| 1. Erosive esophagitis | 17 (4) | 91 (15.4) | 4.40 (2.18–8.87)* | ||||
| 2. Erosive gastritis | 46 (10.7) | 67 (11.3) | 1.06 (0.63–1.79) | ||||
| 3. Esophageal varices | 0 (0) | 10 (1.7) | 15.47 (0.37–645.5) | ||||
| 4. Duodenal ulcer | 9 (2.1) | 91 (15.4) | 8.47 (3.39–21.17)* | ||||
| 5. Barrett’s esophagus | 14 (3.3) | 3 (0.5) | 0.15 (0.029–0.78)* | ||||
| 6. Gastric ulcer | 0 (0) | 18 (3) | 27.64 (0.68–1111.64) | ||||
| 7. Erosive duodenitis | 37 (8.6) | 66 (11.2) | 1.32 (0.76–2.31) | ||||
| 8. Gastric polyps | 16 (3.7) | 13 (2.2) | 0.57 (0.21–1.53) | ||||
| 9. Gastric cancer | 0 (0) | 7 (1.2) | 10.99 (0.25–474.45) | ||||
| 10. Esophageal cancer | 0 (0) | 10 (1.7) | 15.47 (0.37–645.55) | ||||
| 11. Esophageal stenosis | 6 (1.4) | 3 (0.5) | 0.35 (0.05–2.23) | ||||
| Not clinically relevant | |||||||
| 1. Normal | 246 (57.4) | 89 (15) | 0.13 (0.08–0.19)* | ||||
| 2. Nonerosive gastritis | 12 (2.8) | 65 (11) | 4.28 (1.87–9.79)* | ||||
| 3. Non erosive duodenitis | 0 (0) | 6 (1) | 9.51 (0.21–417.96) | ||||
| 4. Hiatus hernia | 25 (5.8) | 52 (8.8) | 1.55 (0.81–2.97) | ||||
| Total | 428 | 591 |
*p < 0.01